Blog
Vixiar Medical Taking up Residence at The LaunchPort™ in Port Covington

Vixiar Medical announced today that it will be moving its HQ office, which includes executive, engineering and manufacturing functions to The LaunchPort™ Accelerator at the City Garage in Port Covington. The LaunchPort™, and its affiliated operation The Factory™, provide a full range of manufacturing and business services to its Residents.

Vixiar Medical recently closed a $1.5 million financing round and is preparing for regulatory submissions and then commercial launch. Local investors included TEDCO and the Abell Foundation. “We are very excited about The LaunchPort™ concept and the services it brings us at this stage of our development,” said Kevin Thibodeau, CEO of Vixiar. “We are also committed to bringing jobs to the City of Baltimore and contributing to the growth of a robust medical technology community in the State of Maryland.” Vixiar will maintain an existing business development office in Anne Arundel County.

“We are excited to have Vixiar join us, as they are representative of the emerging high value medical technologies that the State and its institutions are capable of producing,” said Robert Storey, Managing Partner of The LaunchPort™. “This moves us forward towards our strategy of growing and anchoring medical technology manufacturing within the city of Baltimore”.

About The LaunchPort™ Accelerator
The LaunchPort™ is a second stage accelerator for medical technology companies that are nearing or have recently completed regulatory approval. It offers a full range of production capabilities that enable emerging growth companies to efficiently launch their products into the market.

About Vixiar Medical, Inc.
Vixiar Medical, Inc., develops non-invasive, cost effective devices and systems for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden. The Company’s first product, Indicor™, is a handheld point of care device and digital platform for monitoring worsening heart failure. Headquartered in Annapolis, Maryland, the Company is a spin-out of Johns Hopkins. For more information, go to http://www.vixiar.com.


Vixiar Medical Raises $1.5 Million in Seed Round Financing

US and global investors join company to help launch first product Indicor™, a non-invasive device for monitoring worsening heart failure.

 Annapolis, MD – July 18, 2017 – Vixiar Medical, Inc., a privately held Maryland company dedicated to the development of non-invasive devices and systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round financing of over $1.5 million.

Proceeds will be used to complete regulatory submissions and fund final engineering and initial production of the Company’s first product, Indicor™, a non-invasive point of care monitoring technology for estimating cardiac filling pressure.  The investment group includes representation from Asia, Europe and the US including the Abell Foundation, Kacero Holdings, BV TEDCO and a Chinese medical device and services investment firm.

“We are excited to receive the support of this group of local and global investors and move forward to achieve our critical milestones including commercialization of our first technology,” said Kevin Thibodeau, Vixiar CEO. “Heart failure is a growing global healthcare challenge and we are eager to offer clinicians a non-invasive, cost-effective solution for identifying early signs so they can intervene earlier and avoid costly hospitalizations.”

About Vixiar Medical™

Vixiar Medical, Inc., develops non-invasive, cost-effective devices and systems for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden. The Company’s first product, Indicor™, is a handheld point of care device and digital platform for monitoring worsening heart failure. Headquartered in Annapolis, Maryland, the Company is a spinout of Johns Hopkins. For more information, go to www.vixiar.com.

 About Abell Foundation

The Abell Foundation is a private foundation dedicated to the enhancement of the quality of life in Maryland, with a particular focus on Baltimore City. The Foundation places a strong emphasis on opening the doors of opportunity to the disenfranchised, believing that no community can thrive if those who live on the margins of it are not included.  Consistent with its mission, the Foundation has allocated a portion of its investment portfolio to early-stage companies that offer significant social and economic benefits to the people of Baltimore City, including several investments in innovative medical devices. For more information, go to http://www.abell.org/

About Kacero Holdings, BV

Kacero Holdings, BV is the investment arm of pharmaceutical and device entrepreneur, Paul Robberts of Maastricht, Netherlands.  Paul founded Romedic BV, a market share leading respiratory equipment and services business which he sold to Mediq NV in 2011 after 21 years of rapid revenue and profit growth. Paul currently owns and operates several other ventures, including Cresco Pharma, BV, a pharmaceutical distribution business specialized in antibiotics, IV and inhalation and asthma therapeutics, and Syrolab, BV, an innovative laboratory diagnostics business.  For more information, go to http://www.crescopharma.nl/  http://www.syrolab.nl/

About TEDCO

TEDCO’s mission is to facilitate the creation of tech businesses and foster their growth throughout the state, through the commercialization of technology. Nationally known as more than a seed/early-stage funding and support resource, TEDCO has invested in more than 400 seed investments for nearly 20 years through 8 funding and 6 mentoring and education programs. TEDCO’s $22 million awarded to start-ups resulted in $1 billion follow-on funding. This investment is through TEDCO’s Life Science Investment Fund (LSIF) and follows their 2015 investment in Vixiar.  For more information, go to http://tedco.md/

The VIC Investor Network

The VIC Investor Network (VIN) was formed in 2013 to place seed capital investments of $250,000 into every new company founded or co-founded by VIC Technology Venture Development.  These companies are based on the most commercially promising technologies exclusively licensed from top research institutions across the country. From breakthrough medical products to innovative water treatment technologies, the portfolio companies have both great commercial opportunity and the potential to impact important problems facing society and the world. In addition to being based on the best of the best new technologies sourced from a pool of over $150 billion of federally sponsored research, the companies each feature outstanding executive management and product development teams.


Vixiar Medical Announces Appointment of Kevin Thibodeau as Chief Executive Officer

January 16, 2017, Annapolis, MD

Vixiar Medical, Inc. announced today that Kevin Thibodeau has been appointed Chief Executive Officer of the medical device company, effective immediately.

“This is perfect timing for Kevin to come on board”, said Vixiar Chairman Robert Storey. “Kevin has a strong track record in medical device market development and revenue growth, particularly in building new standards of care and disruptive technologies. Kevin has a stellar relationship with the clinical community and global hospital ecosystem and excels at educating, and collaborating with, users and payers when it comes to pioneering technology. We are at a tipping point in dealing with chronic disease, where the current trajectory simply isn’t sustainable for patients, providers or payers. Readmissions, in particular, place a great economic strain on the system and are proven to increase morbidity and mortality in patients. The opportunity we have in front of us is to improve the efficiency of care, by monitoring patients more closely through the continuum of care and doing a better job at diagnosing problems sooner to allow for earlier intervention. This is particularly true with heart failure, where hospitalizations are so high and where the existing diagnostic solutions are either too invasive, too expensive, or inconvenient. Our mission at Vixiar is to provide solutions that overcome these obstacles and improve care while bringing dramatic cost savings to the system. I can’t think of a better person to lead this effort.”

Vixiar Medical has developed a non-invasive, cost effective and accurate device for point-of-care early detection of worsening heart failure, the Indicor™, based on technology developed at Johns Hopkins School of Medicine. The device is coupled with a digital health platform that includes a patient app and cloud-based clinical analytics for continuous disease management.

Mr. Thibodeau has spent his career in the medical device and medical information industries, most recently with Vapotherm, Inc., where he led the market development of what has become a new global standard of care in non-invasive respiratory support. “I am excited to be leading Vixiar and building a business that brings such a clear clinical and economic value proposition to the health care system and heart failure patients. The Vixiar solution is a convergence of the best of digital health with a truly unique and reliable diagnostic tool for addressing heart failure.”

Vixiar’s technology was originally developed by Johns Hopkins cardiologist Dr. Harry Silber, with whom the company was co-founded with VIC Technology Venture Development (offices in Annapolis, Boston, Fayetteville, and San Diego). It is a an excellent example of collaboration between private, public and institutional interests, having been a recipient of funds from the Maryland Department of Commerce and TEDCO Innovation Initiative, funds to support clinical research from the Johns Hopkins Coulter Partnership and Discovery Funds, the Anne Arundel Economic Development Corporation and private equity investment. The Company has its business offices in Anne Arundel County, has recruited executives from the State, and is in discussion to establish manufacturing and offices within the city of Baltimore.

About Vixiar Medical™
Vixiar Medical, Inc., develops non-invasive, cost effective devices and systems for monitoring cardiopulmonary diseases, particularly those with significant clinical and economic burden. The Company’s first product, Indicor™, is a handheld point of care device for monitoring worsening heart failure. Headquartered in Annapolis, Maryland, it is a portfolio company of VIC Technology Venture Development.


Vixiar Medical Presents at Coulter Foundation Translational Research Investment Forum in Palo Alto

Company Chairman introduces new, non-invasive congestive heart failure monitoring device to be deployed in hospitals, physicians’ offices, and home markets, pending regulatory approval, by end of year.

Vixiar Medical, Inc. announced today that Robert Storey, Maryland Managing Director of VIC Technology Venture Development™ and the Chairman of Vixiar Medical, was a presenter at the Coulter Foundation Investor Forum held at Stanford University’s Francis C. Arrillaga Alumni Center in Palo Alto, California.

The Wallace H. Coulter Foundation funds translational research in biomedical engineering through endowment and grants to sixteen of the nation’s top biomedical engineering schools. The program funds joint research between biomedical engineering investigators and clinicians, and supports the most promising technologies that can progress towards commercial development and enter the clinical practice. The top 25 start-up companies spun out of this process were invited to present at the investor forum.

The Vixiar product, based on technology licensed from Johns Hopkins University, allows rapid and repetitive assessment of cardiac filling pressures – a critical measurement in the management of heart failure hospital readmissions. The inexpensive wireless device can be used at the point of care by a physician/nurse, or the patient can utilize a self-directed set of procedures to conduct the tests remotely and non-invasively over several minutes. The normal process for obtaining cardiac filling pressures requires an invasive catheterization procedure at a lab, in which a pressure catheter is run through the patient’s artery into the heart chambers for direct measurement.

Vixiar prototypes have been tested on several hundred patients to date, and are currently being used in four separate clinical trials. Vixiar expects its heart monitor to be deployed in hospitals, physicians’ offices, and home markets with an initial release, pending regulatory approval, by the end of 2015.

About CHF
Congestive Heart Failure is being treated in approximately 6 million people in the US and about 25 million worldwide. It accounts for 1.2 million hospital admissions in the US each year and is the number one cause of hospital readmissions within 30 days of discharge. Hospital treatment costs are about $40 billion per year, and nearly 10% of those expenditures are unreimbursed due to readmissions that occur within 30 days. Improved monitoring of increasing cardiac filling pressures is considered the important criteria to allow intervention before a patient progresses to hospitalization.

About Vixiar Medical™
Vixiar Medical, Inc, is involved in the development of innovative technologies for the treatment and monitoring of cardiopulmonary disease. Headquartered in Annapolis, Maryland, it is part of the VIC Technology group of companies. Contact Robert Storey, Chairman of Vixiar, and Maryland Managing Director of VIC Technology Venture Development, at bstorey@victvd.com or (443) 603-0212. http://www.vixiar.com

About VIC Technology Venture Development™
VIC Technology is a for-profit firm involved in the licensing and formation of companies that are based on technologies from university and federal labs. The group currently has 14 companies in its active portfolio and maintains offices in Annapolis, Boston, and Fayetteville, Arkansas. http://www.victvd.com


Vixiar Medical Receives BioMaryland Development Award for Non-invasive Heart Failure Monitor

Company plans deployment of congestive heart failure monitoring device to hospitals, physicians’ offices, and home markets, pending regulatory approval, by end of year.

Vixiar Medical, Inc. announced today that it was awarded a $200,000 grant by the State of Maryland to accelerate the commercialization of its non-invasive congestive heart failure (CHF) device. The BioMaryland Center made the awards on a competitive basis to six life sciences companies, with preference given to projects that improve patient outcomes and reduce health care costs.

The Vixiar product, based on technology licensed from Johns Hopkins University, allows rapid and repetitive assessment of cardiac filling pressures – a critical measurement in the management of heart failure hospital readmissions. The inexpensive wireless device can be used at the point of care by a physician/nurse, or the patient can utilize a self-directed set of procedures to conduct the tests remotely and non-invasively over several minutes. The normal process for obtaining cardiac filling pressures requires an invasive catheterization procedure at a lab, in which a pressure catheter is run through the patient’s artery into the heart chambers for direct measurement.

Vixiar prototypes have been tested on several hundred patients to date, and are currently being used in four separate clinical trials. Vixiar’s heart monitor is expected to be deployed in hospitals, physicians’ offices, and home markets.

“We are grateful to the State of Maryland and their recognition of the potential for this innovative technology”, said Robert Storey, Chairman of Vixiar Medical and Managing Director of VIC Technology Venture Development, the firm that initially spun out the technology from Johns Hopkins. “We believe that we can make a major impact on the management of CHF in Maryland and nationally, and are directing these funds to accelerate our regulatory approvals”.

For this year’s awards, the BioMaryland Center launched a new partnership with Maryland’s Department of Health and Mental Hygiene (DHMH) and the Center for Medical Technology Policy (CMTP) to incorporate improved health care quality and cost reduction criteria into the selection process.

“These awards provide critical funding and help to ensure that the life-saving research being done at these companies has the opportunity to move to the commercial marketplace and potentially impact millions around the world,” said Maryland’s Department of Business and Economic Development Secretary Mike Gill.

About CHF
Congestive Heart Failure is being treated in approximately 6 million people in the US and about 26 million worldwide. It accounts for 1.2 million hospital admissions in the US each year and is the number one cause of hospital readmissions within 30 days of discharge. Hospital treatment costs are about $40 billion per year, and nearly 10% of those expenditures are unreimbursed due to readmissions that occur within 30 days. Improved monitoring of increasing cardiac filling pressures is considered the important criteria to allow intervention before a patient progresses to hospitalization.

About Vixiar Medical™
Vixiar Medical, Inc, is involved in the development of innovative technologies for the treatment and monitoring of cardiopulmonary disease. Headquartered in Annapolis, Maryland, it is part of the VIC Technology group of companies. Contact Robert Storey, Chairman of Vixiar, and Maryland Managing Director of VIC Technology Venture Development, at bstorey(at)victvd(dot)com or (443) 603-0212. http://www.vixiar.com

About VIC Technology Venture Development™
VIC Technology is a for-profit firm involved in the licensing and formation of companies that are based on technologies from university and federal labs. The group currently has 14 companies in its active portfolio and maintains offices in Annapolis, Boston, and Fayetteville, Arkansas. http://www.victvd.com